Abstract: The invention relates to the use of specific tripeptides for the treatment of postlesional diseases of ischemic, traumatic or toxic origin. The tripeptide derivatives satisfy formula (I), wherein X represents OH, (C1-5)alkoxy, NH2, NH—C1-5-alkyl, N(C1-5 alkyl)2; R1 is a residue derived from any of the amino acids Phe, Tyr, Trp, Pro, each of which may optionally be substituted by a (C1-5) alkoxy group, a (C1-5) alkyl group or a halogen atom, and Ala, Val, Leu, or Ile; R2 is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu and Asn; R3 and R4 independently represent H, OH, (C1 –C5) alkyl, or (C1-5)alkoxy, provided that R3 and R4 are not both OH or (C1-5)alkoxy; R5 represents H, OH, (C1-5)alkyl or (C1-5)alkoxy; and wherein R0 preferably represents a cinnamoyl residue; or pharmaceutically acceptable salts thereof.

Abstract: The invention relates to the use of specific tripeptides for the treatment of neurodegenerative diseases, and to pharmaceutical compositions comprising the tripeptides. The tripeptide derivatives satisfy the following formula (I): wherein X represents OH, (C1-5) alkoxy, NH2, NH—C1-5-alkyl, N(C1-5 alkyl)2; R1 is a residue derived from one of the amino acids Phe, Tyr, Trp, Pro, which each may be optionally substituted with one or more (C1-5)alkoxy groups, (C1-5)alkyl groups or halogen atoms, as well as Ala, Val, Leu or Ile; R2 is a residue derived from one of the amino acids Gly, Ala, Ile, Val, Ser, Thr, Leu and Pro; Y1 and Y2 independently from each other represent H or (C1-5)alkyl; R3 and R4 independently from each other represent H, OH, (C1-5)alkyl or (C1-5)alkoxy, provided that R3 and R4 are not both OH or (C1-5)alkoxy; and R5 represents H, OH, (C1-5)alkyl or (C1-5)alkoxy; or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to the use of specific tripeptides for the treatment of postlesional diseases of ischemic, traumatic or toxic origin. The tripeptide derivatives satisfy the following formula (I): (see formula I as in paper form) wherein X represents OH, (C1-5) alkoxy, NH2, NH—C1-5-alkyl, N(C1-5 alkyl)2; R1 is a residue derived from one of the amino acids Phe, Tyr, Trp, Pro, which each may be optionally substituted with one or more (C1-5) alkoxy groups, (C1-5) alkyl groups or halogen atoms, as well as Ala, Val, Leu or Ile; R2 is a residue derived from one of the amino acids Gly, Ala, Ile, Val, Ser, Thr, and Pro; Y1 and Y2 independently from each other represent H or (C1-5) alkyl; R3 and R4 independently from each other represent H, OH, (C1-5) alkyl or (C1-5) alkoxy, provided that R3 and R4 are not both OH or (C1-5) alkoxy; and R5 represents H, OH, (C1-5) alkyl or (C1-5) alkoxy; or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to the use of specific tripeptides for the treatment of neurodegenerative diseases. The tripeptide derivatives satisfy the following formula (I): wherein X represents OH, (C1-5)alkoxy, NH2, NH—C1-5-alkyl, N(C1-5alkyl)2; R1 is a residue derived from any of the amino acids Phe, Tyr, Trp, Pro, each of which may optionally be substituted by a (C1-5)alkoxy group, a (C1-5)alkyl group or a halogen atom, and Ala, Val, Leu, or Ile; R2 is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu and Asn; R3 and R4 independently represent H, OH, (C1-5)alkyl, or (C1-5)alkoxy, provided that R3 and R4 are not both OH or (C1-5)alkoxy; R5 represents H, OH, (C1-5)alkyl or (C1-5)alkoxy; and wherein R0 preferably represents a cinnamoyl residue; or pharmaceutically acceptable salts thereof.

Abstract: The invention relates to the use of specific tripeptides for the treatment of neurodegenerative diseases, and to pharmaceutical compositions comprising the tripeptides. The tripeptide derivatives satisfy the following formula (I): wherein X represents OH, (C1-5) alkoxy, NH2, NH—C1-5-alkyl, N(C1-5 alkyl)2; R1 is a residue derived from one of the amino acids Phe, Tyr, Trp, Pro, which each may be optionally substituted with one or more (C1-5)alkoxy groups, (C1-5)alkyl groups or halogen atoms, as well as Ala, Val, Leu or Ile; R2 is a residue derived from one of the amino acids Gly, Ala, Ile, Val, Ser, Thr, Leu and Pro; Y1 and Y2 independently from each other represent H or (C1-5)alkyl; R3 and R4 independently from each other represent H, OH, (C1-5)alkyl or (C1-5)alkoxy, provided that R3 and R4 are not both OH or (C1-5)alkoxy; and R5 represents H, OH, (C1-5)alkyl or (C1-5)alkoxy; or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to the use of specific tripeptides for the treatment of postlesional diseases of ischemic, traumatic or toxic origin. The tripeptide derivatives satisfy formula (I), wherein X represents OH, (C1-5)alkoxy, NH2, NH—C1-5-alkyl, N(C1-5 alkyl)2; R1 is a residue derived from any of the amino acids Phe, Tyr, Trp, Pro, each of which may optionally be substituted by a (C1-5) alkoxy group, a (C1-5) alkyl group or a halogen atom, and Ala, Val, Leu, or Ile; R2 is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu and Asn; R3 and R4 independently represent H, OH, (C1-C5) alkyl, or (C1-5)alkoxy, provided that R3 and R4 are not both OH or (C1-5)alkoxy; R5 represents H, OH, (C1-5)alkyl or (C1-5)alkoxy; and wherein R0 preferably represents a cinnamoyl residue; or pharmaceutically acceptable salts thereof.

Abstract: The invention relates to the use of specific tripeptides for the treatment of postlesional diseases of ischemic, traumatic or toxic origin. The tripeptide derivatives satisfy the following formula (I): (see formula I as in paper form) wherein X represents OH, (C1-5) alkoxy, NH2, NH—C1-5-alkyl, N(C1-5 alkyl)2; R1 is a residue derived from one of the amino acids Phe, Tyr, Trp, Pro, which each may be optionally substituted with one or more (C1-5) alkoxy groups, (C1-5) alkyl groups or halogen atoms, as well as Ala, Val, Leu or Ile; R2 is a residue derived from one of the amino acids Gly, Ala, Ile, Val, Ser, Thr, and Pro; Y1 and Y2 independently from each other represent H or (C1-5) alkyl; R3 and R4 independently from each other represent H, OH, (C1-5) alkyl or (C1-5) alkoxy, provided that R3 and R4 are not both OH or (C1-5) alkoxy; and R5 represents H, OH, (C1-5) alkyl or (C1-5) alkoxy; or a pharmaceutically acceptable salt thereof.

Abstract: The principal activity of the amides of ethanol-.beta.-aminophosphoric acid with active moieties having anti-inflammatory and analgesic activity (FANS) remains substantially unchanged but they have considerably lower toxicity particularly in terms of damage to the stomach.The method for their preparation is also described.

Abstract: The adhesive plaster for the transdermal administration of estradiol or mixture estradiol/progestin is composed of an impermeable carrier film and of an adhesive composition. The latter represents a matrix or reservoir layer and is composed of a solvent-based polyacrylate or polyisobutylene adhesive which contains a saturated or unsaturated fatty acid with 6 to 18 C atoms as permeability enhancer, estradiol or mixture estradiol/progestin as active substance and optionally propylene glycol as solvent.The adhesive plaster is used for the systemic administration of hormones in hormone replacement therapy for a time of at least 3 days.

Abstract: The thiolic salts of erythromycin and of the propionic ester of erythromycin with thenoyl alpha-mercaptopropionylglycine find therapeutical use in the cases in which erythromycin or its propionic ester are used and are generally endowed with very low toxicity and high hematic levels.

Abstract: The present invention relates to [(2-oxo-3-tetrahydrothienylcarbamoyl)-alkylthio]-acetic acids, their salts and esters of formula: ##STR1## in which n is 0 or 1, one of the substituents R.sub.1 and R.sub.2 is a hydrogen atom or a methyl group and the other represents a group -S-CH.sub.2 -COOR.sub.3, where R.sub.3 is a hydrogen atom or an alkali metal or a lower alkyl group or a group: ##STR2## It also relates to a process for preparing said acids, salts and esters, and to the drugs containing same.

Abstract: The thiolic salts of erythromycin and of the propionic ester of erythromycin with thenoyl alpha-mercaptopropionylglycine find therapeutical use in the cases in which erythromycin or its propionic ester are used and are generally endowed with very low toxicity and high hematic levels.